Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects
GENEBRO
1 other identifier
interventional
44
1 country
1
Brief Summary
The respiratory epithelium plays a leading role in the development of allergic respiratory disease with barrier function alteration, its repair mechanisms, of anti-viral fight and the ability to induce by itself Th2 responses. The majority of allergic asthmatic patients have reached concomitant ENT: the concept of "one airway, one disease." Access to this material of epithelial study in the different phenotypes of the disease appears to be crucial. Nasal and bronchial epithelial tissues reveal essential differences in particular related to their environment (remodeling less intense and a lower sensitivity to the virus in the nose), but they nevertheless share many common cellular characteristics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2013
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 13, 2013
CompletedFirst Posted
Study publicly available on registry
August 15, 2013
CompletedStudy Start
First participant enrolled
November 29, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 28, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 7, 2017
CompletedMarch 24, 2026
March 1, 2026
3 years
August 13, 2013
March 20, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
genic expression profile of the epithelium
3 months after inclusion
Study Arms (3)
allergic rhinitis
EXPERIMENTALallergic rhinitis and asthma
EXPERIMENTALwitnesses
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- age ≥ 18 years and \<30 years
- isolated allergic rhinitis according to clinical criteria ARIA
- absence of asthma whose diagnosis is made based on clinical criteria or mild to moderate persistent asthma controlled with a diagnosis is made based on clinical criteria
You may not qualify if:
- recent rhino-bronchial infection (\<6 weeks)
- asthma exacerbation in the previous 6 weeks
- Chronic disease may in the opinion of the investigators interfere with the results of the study or expose them to additional risk.
- Treatment with nasal corticosteroids, inhaled or systemic in the past 6 weeks
- Current smoking no history of smoking or not smoking for at least 12 months and weaned smoking history \<5 pack-years)
- Special Needs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Pasteur
Nice, 06003, France
Related Publications (1)
Giovannini-Chami L, Paquet A, Sanfiorenzo C, Pons N, Cazareth J, Magnone V, Lebrigand K, Chevalier B, Vallauri A, Julia V, Marquette CH, Marcet B, Leroy S, Barbry P. The "one airway, one disease" concept in light of Th2 inflammation. Eur Respir J. 2018 Oct 25;52(4):1800437. doi: 10.1183/13993003.00437-2018. Print 2018 Oct.
PMID: 30190271RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 13, 2013
First Posted
August 15, 2013
Study Start
November 29, 2013
Primary Completion
November 28, 2016
Study Completion
May 7, 2017
Last Updated
March 24, 2026
Record last verified: 2026-03